Abstract
Constitutional indocyanine green excretion defect (CIED) is a rare disorder characterized by markedly delayed plasma indocyanine green disappearance (ICG-R15 > 50%) despite normal results from conventional liver function tests. We present a case involving a 60-year-old woman diagnosed with CIED, representing the first documented case in a Chinese patient without underlying liver disease. Whole-exome sequencing revealed no pathogenic variants in established ICG transporter genes (SLCO1B1, SLCO1B3, SLC10A1, and ABCC2), suggesting a novel pathogenesis independent of known transporter deficiencies.
The ICG Paradox
In hepatology, the Indocyanine Green (ICG) clearance test is a gold standard for assessing liver functional reserve. Typically, a high retention rate (ICG-R15 > 10%) indicates significant liver damage or cirrhosis. However, patients with CIED exhibit massive retention (>50%) despite having entirely normal liver function. Historically, this condition was thought to be caused by genetic mutations in the OATP1B1 and OATP1B3 transporters—the "gates" of liver cells.
Investigating the "Broken Gate" Theory
To investigate this case, researchers used a multi-dimensional approach to rule out standard causes of ICG retention. Clinical testing confirmed the patient's liver was healthy, with normal enzyme panels and no signs of scarring.
Functional imaging via Gd-EOB-DTPA-enhanced MRI provided a critical clue. This contrast agent utilizes the same cellular transporters as the ICG dye.
The MRI showed normal contrast uptake in the hepatobiliary phase. This "Transporter Paradox" proves that the OATP transporters are structurally intact and functional, effectively debunking the theory that the "gates" were simply broken in this patient.
Genomic Insights and the Growth Hormone Hypothesis
When Whole-Exome Sequencing (WES) returned no pathogenic variants in the four known transporter genes (SLCO1B1, SLCO1B3, SLC10A1, and ABCC2), the team looked for alternative regulatory pathways.
Interaction network analysis identified a variant of uncertain significance (VUS) in the GH1 gene (c.615C > G). The researchers hypothesize that the GH-JAK2-STAT5 signaling axis acts as a regulatory "master switch" for liver transporters. If this signaling is disrupted, the liver may fail to process ICG specifically, even if the physical machinery is present.
Clinical Implications
This study expands the known geographic and ethnic footprint of CIED, marking the first documented case in a Chinese patient without liver disease. Crucially, it serves as a clinical warning: relying solely on ICG tests can lead to "false positives" for liver dysfunction. This could potentially cause surgeons to deny life-saving operations to patients who possess adequate liver reserve but have this rare metabolic quirk.
Future Directions
As a single case report, the link between the GH1 variant and ICG excretion remains a strong hypothesis. Future work will focus on in vitro validation to see if the variant directly affects transporter expression and large-scale screening of the growth hormone axis in other patients with unexplained high ICG retention.
Summary updated